Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical and Experimental Dermatology|March 16, 2026
Relationships between Botulinum Toxin type, administer, and location with odds of adverse eventsLee Smith, Masoud Rahmati, Jose Francisco Lopez Gil, et al.
Cancers|January 11, 2024
Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian CancerRobert D Morgan, George J Burghel, Helene Schlecht, et al.
Nature Cancer|February 29, 2020
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapySara Valpione, Elena Galvani, Joshua Tweedy, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2022
Tumour infiltrating B cells discriminate checkpoint blockade-induced responsesSara Valpione, Luca G Campana, John Weightman, et al.
British Journal of Cancer|March 9, 2022
BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?Robert D Morgan, George J Burghel, Nicola Flaum, et al.
Cancers|February 11, 2023
Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?Robert D Morgan, George J Burghel, Nicola Flaum, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition geneRobert D Morgan, George J Burghel, Nicola Flaum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
Journal of Clinical Pathology|June 23, 2022
Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancerRobert D Morgan, George J Burghel, Nicola Flaum, et al.
Pageof 3